Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
HC Surgical SpecialistsSGX:1B1 +1.45%63 ROE % is 27.38% as of May. 2026, which is 13% below its 10-year median of 31.31. GuruFocus rates SGX:1B1 with a GF Score™ of 63/100 and a GF Value™ of S$0.30 (Modestly Overvalued). The stock has 2 warning signs investors should review. Among 198 Medical Diagnostics & Research companies, HC Surgical Specialists ranks better than 93.94% on this metric.
HC Surgical Specialists (SGX:1B1) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is two times the semi-annual (May. 2026) net income data. The Revenue data used here is two times the semi-annual (May. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, HC Surgical Specialists's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HC Surgical Specialists ROE % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, HC Surgical Specialists's ROE % distribution charts can be found below:
* The bar in red indicates where HC Surgical Specialists's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (May. 2026) net income data.
ROE % is displayed in the 30-year financial page.
HC Surgical Specialists (SGX:1B1) has a ROE % of 27.38% as of May. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on HC Surgical Specialists and its competitors. This is 13% below median its historical median of 31.31. Over the past decade, HC Surgical Specialists' ROE % has ranged from 16.37 to 61.29. According to the industry distribution chart, HC Surgical Specialists ranks #12 out of 198 companies in the Medical Diagnostics & Research industry, placing it in the top 6.1%.
Is HC Surgical Specialists' ROE % too high?
HC Surgical Specialists' current ROE % of 27.38% is 13% below median its 10-year median of 31.31. Over the past 10 years, this metric has ranged from a low of 16.37 to a high of 61.29. Based on the distribution chart, HC Surgical Specialists ranks #12 out of 198 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, HC Surgical Specialists has a GF Score™ of 63/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does HC Surgical Specialists' ROE % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, HC Surgical Specialists ranks #12 out of 198 companies for ROE %. This places HC Surgical Specialists in the top 6% of its industry — outperforming the majority of peers. Historically, HC Surgical Specialists' own ROE % has ranged from 16.37 to 61.29 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Medical Diagnostics & Research company?
A good ROE % depends on the Medical Diagnostics & Research industry context. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on HC Surgical Specialists and its competitors. HC Surgical Specialists's current ROE % is 27.38%, which is 13% below median its own 10-year median of 31.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HC Surgical Specialists stock overvalued right now?
Based on GuruFocus' analysis, HC Surgical Specialists (SGX:1B1) is currently considered Modestly Overvalued. The stock's GF Value™ is S$0.30, compared to a current price of S$0.35 — trading 16.7% above its estimated fair value. The current ROE % is 27.38%, which is 13% below median its 10-year median of 31.31. HC Surgical Specialists' overall GF Score™ is 63/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For HC Surgical Specialists (SGX:1B1), the current ROE % is 27.38% as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is HC Surgical Specialists (SGX:1B1) Overvalued in 2026?
Based on GuruFocus' analysis, HC Surgical Specialists stock appears to be overvalued.
The current stock price of S$0.35 is trading 16.7% above its estimated GF Value™ of S$0.30.
GuruFocus considers HC Surgical Specialists to be Modestly Overvalued.
Key valuation signals for SGX:1B1:
ROE %: 27.38% (13% below median its 10-year median of 31.31)
GF Value™: S$0.30 vs. price of S$0.35 (16.7% above fair value)
No single metric tells the full story. See the SGX:1B1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
HC Surgical Specialists Ltd is a medical services group. The company is engaged in providing endoscopic procedures, including gastroscopies and colonoscopies, and general surgery services. The operating segment of the company is the healthcare segment. Geographically, it operates only in Singapore. The company has its facilities center and clinics at various places in Singapore.
63GF Score
Get the complete analysis for SGX:1B1
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SGX:1B1 has been successfully added to your 
